I am a bit disappointed, most of the doctors interviewed for the original article are Italian, yet in Italy this approach is not widespread….bah
Metastasis-directed therapy (MDT), particularly stereotactic body radiotherapy (SBRT), is transforming metastatic prostate cancer treatment by offering tailored strategies that move beyond traditional lifelong androgen deprivation therapy (ADT). Studies like STOMP and ORIOLE have shown that MDT can significantly delay the initiation of ADT and improve progression-free survival. Combining MDT with short-term ADT, as explored in the EXTEND trial, has further enhanced outcomes, allowing patients to maintain normal testosterone levels longer. In cases of oligoprogressive castration-resistant prostate cancer, the ARTO trial demonstrated that MDT could delay the need for additional systemic therapies. Additionally, the PROLONG study found that MDT, when used alongside systemic therapies for de novo low-volume hormone-sensitive prostate cancer, improved survival. Even in polymetastatic disease, MDT has proven to be a safe and feasible option. These findings indicate that MDT is not only effective but also adaptable, offering patients more personalized treatment approaches while improving their quality of life.